BioMarin Acquires Alesta Therapeutics to Secure ALE1, an Oral HPP Therapy
$490 Million Deal Secures Clinical Assets and Team
BioMarin Pharmaceutical (BMRN) has acquired Alesta Therapeutics, a Netherlands-based clinical-stage biotech, to gain access to ALE1, a candidate therapy for hypophosphatasia (HPP). The deal consists of an upfront payment of $275 million in cash and potential development and regulatory milestone payments of up to $215 million, totaling $490 million. This is a straightforward acquisition with no royalties or equity stake, with 44% of the value tied to future performance, sharing the risk of early clinical failure. BioMarin has quickly bolstered its rare bone disease pipeline, complementing the growth of Voxzogo (vosoritide).
First-in-Class Oral Therapy Targeting ENPP1
ALE1 is an investigational, small-molecule oral therapy that competitively inhibits the ATP-binding site of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). In HPP, caused by mutations in the ALPL gene leading to a deficiency of tissue-nonspecific alkaline phosphatase (TNAP), inorganic pyrophosphate (PPi) accumulates, inhibiting bone and tooth mineralization. ALE1 targets the upstream mechanism of PPi production. This represents a different approach from standard-of-care enzyme replacement therapy, aiming to modulate disease metabolism with an oral treatment. A key clinical differentiator is the potential to reduce the burden of frequent injections for adult HPP patients.
Phase 1/2a Trial Evaluating Safety, PK, and PD
ALE1 is being evaluated in a Phase 1/2a trial (NCT07179640) involving 120 healthy adults and adult HPP patients to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD). The trial began in September 2025 and is expected to complete Phase 1 in January 2027, and has not yet demonstrated efficacy. The FDA granted ALE1 Orphan Drug Designation for infantile-onset HPP in June 2026, recognizing its reversible, competitive ENPP1 inhibition mechanism, but has not approved it for marketing. Therefore, the acquisition value depends on initial safety data, changes in PPi biomarkers, and the potential for a Phase 2b/3 trial design.
Challenging the Strensiq Monopolistic Market with Improved Convenience
The current standard of care is Strensiq (asfotase alfa) from AstraZeneca (AZN)'s Alexion, a bone-targeted recombinant TNAP enzyme replacement therapy that requires subcutaneous injections 3-6 times per week. Strensiq was approved in Japan on July 2015, in Europe on August 28, 2015, and in the United States on October 23, 2015, and the FDA review process did not raise any contentious issues, so an advisory committee was not convened. In 2025, global sales were $1.678 billion, a 19% increase, demonstrating the substantial commercial market size and high entry value for HPP. A competing pipeline product, REV102, an oral ENPP1 inhibitor from Rallybio (RLYB) and Recursion Pharmaceuticals (RXRX), is in Phase 1 clinical trials, and ALE1's leading position will depend on development speed and long-term safety.
ALE1 is a Phase 1/2a ENPP1 inhibitor that offers the first oral treatment option in the HPP market, which generated $1.678 billion in sales in 2025 with Strensiq as the primary therapy. BioMarin has mitigated early asset risk by committing to an upfront payment of $275 million and tying up to $215 million to development and regulatory milestones. In the short term, clinical costs and acquisition-related R&D expenses will pressure profitability, but with PPi biomarker and adult patient data, it can establish a growth driver for rare bone diseases following Voxzogo. From an R&D perspective, the clinical validation of ENPP1 inhibition, rather than TNAP replacement, represents a turning point in expanding the scope of HPP treatment to adults and late-onset patients. However, competition with REV102, the safety of excessive PPi reduction and potential ectopic calcification, and the Phase 1 results expected in January 2027 will determine the medium- to long-term value.
Source: BioPharma Dive (rss)